NCT00245973View on ClinicalTrials.gov

Study Evaluating Bifeprunox in Bipolar Depression

PHASE3CompletedINTERVENTIONAL
Enrollment

380

Participants

Timeline

Start Date

June 30, 2005

Study Completion Date

October 31, 2007

Conditions
Depression Bipolar
Interventions
DRUG

Bifeprunox

Trial Locations (40)

10021

New York

10024

New York

10305

Staten Island

10467

The Bronx

11559

Lawrence

19149

Philadelphia

20852

Rockville

27103

Winston-Salem

29407

Charleston

30080

Smyrna

32216

Jacksonville

32806

Orlando

33407

West Palm Beach

34208

Bradenton

35216

Birmingham

41042

Florence

44124

Lyndhurst

45242

Cincinnati

45408

Dayton

47802

Terre Haute

48336

Farmington Hills

53223

Brown Deer

63301

Saint Charles

70115

New Orleans

73103

Oklahoma City

74135

Tulsa

75390

Dallas

78756

Austin

84107

Salt Lake City

90210

Beverly Hills

91950

National City

94305

Stanford

96826

Honolulu

97210

Portland

98004

Bellevue

98104

Seattle

06030

Farmington Hills

02114

Boston

08021

Clementon

08057

Moorestown

All Listed Sponsors
collaborator

Solvay Pharmaceuticals

INDUSTRY

lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00245973 - Study Evaluating Bifeprunox in Bipolar Depression | Biotech Hunter | Biotech Hunter